White House

Just one cancer drug—ibrutinib—figures on the CMS list of 10 drugs subject to price negotiations under Medicare Part D
White House

Just one cancer drug—ibrutinib—figures on the CMS list of 10 drugs subject to price negotiations under Medicare Part D
PhRMA sues to block the program

The first 10 drugs selected for price negotiations under Medicare Part D program includes only one oncology drug: ibrutinib (Imbruvica), a tyrosine kinase inhibitor indicated for the treatment of blood cancers, including chronic lymphocytic leukemia and small lymphocytic lymphoma.
Biden renews Cancer Moonshot mission to “cure cancers”; Names Renee Wegrzyn director of ARPA-H
News AnalysisWhite House

Biden renews Cancer Moonshot mission to “cure cancers”; Names Renee Wegrzyn director of ARPA-H

When you are making a point that the country that put humans on the moon also has the capacity to cure cancers, venue and timing matter. On Sept. 12, President Joe Biden chose John F. Kennedy Presidential Library and Museum—and the 60th anniversary of Kennedy’s 1962 moonshot speech—to announce his plan’s latest iteration.